|| List of recent Platelet-related patents
| Activation and aggregation of human platelets and formation of platelet gels by nanosecond pulsed electric fields|
Methods for forming activated platelet gels using nspef's and applying the activated gels to wounds, such as heart tissue after myocardial infarction. The platelets are activated by applying at least one nspef with a duration between about 10 picoseconds to 1 microsecond and electrical field strengths between about 10 kv/cm and 350 kv/cm..
| Graphene platelet fabrication method and graphene platelet fabricated thereby|
The present invention discloses a graphene platelet fabrication method, which comprises step (a): providing a highly-graphitized graphene having a graphitization degree of 0.8-1.0; and step (b): providing a shear force acting on the highly-graphitized graphene to separate the highly-graphitized graphene into graphene platelets, wherein the graphene platelets have a length of 10-500 μm and a width of 10-500 μm and have a single-layer or multi-layer structure. The present invention also discloses a graphene platelet fabricated according to the abovementioned method..
| Silver nanoplate compositions and methods|
Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.
|Transdermal pharmaceutical preparation and administration of tirofiban|
The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition.
|Quinoline derivatives as pi3 kinase inhibitors|
Invented is a method of inhibiting the activity/function of pi3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives..
|Assessment of cardiac health and thrombotic risk in a patient|
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value.
|Antibody polypeptides that antagonize cd40l|
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
|Use of pre-mrna splicing in platelet cells for the diagnosis of disease|
The invention relates to materials and procedures for identifying or using tissue factor (tf) pre-mrna splicing, clk 1 activity or tf-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mrnas to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (tf) pre-mrna splicing in platelets is an indicator of inflammatory and thrombotic disease states.
|Platelet additive solution having a beta-galactosidase inhibitor|
The present invention relates to a platelet additive solution (pas) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of pas components that include a salt, a citrate source, a carbon source, or any combination thereof.. .
A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von willebrand factor-binding peptides (vbps), collagen-binding peptides (cbps) and an active platelet gpiib-iiia-binding peptides (gbps).. .
|Spacer-modified graphene electrode for supercapacitor|
A spacer-modified nano graphene platelet electrode, comprising: (a) multiple nano graphene platelets or sheets having an average thickness smaller than 10 nm; and (b) discrete, non-metallic nano-scaled particles that are disposed between two graphene platelets or sheets to serve as a spacer. In such a spacer-modified graphene electrode, large amounts of electrolyte-accessible pores are formed, enabling the formation of large amounts of electric double layer charges in a supercapacitor, which exhibits an exceptionally high specific capacitance..
Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (prp) and or platelet poor plasma (ppp) can be obtained rapidly and is ready for immediate injection into the host.
|Platelet aggregation test and device|
An assembly for testing platelet aggregation including an electrode subassembly that is mounted in a cuvette subassembly for use with relatively small samples containing platelets.. .
|Expansion medium for cd34-negative stem cells|
This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 μm in diameter; (b) a human fresh frozen plasma (ffp) filtrate free of solid matter greater than 0.22 μm in diameter; (c) heparin; (d) l-glutamine; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the cell growth medium permits the expansion of human cd34− stem cells and wherein the resulting expanded cd34− stem cells retain the ability to differentiate. This invention also provides related cell growth medium supplements, a sterile human platelet lysate and human fresh frozen plasma (ffp) filtrate, kits, cd34− stem cell-containing compositions, and related production and cell expansion methods..
|Compositions and methods for the generation of platelets and methods of use thereof|
Compositions and methods for generating platelets and methods of use thereof are disclosed.. .
|Polyaniline-graphite nanoplatelet materials|
Nanocomposite adsorbent materials and methods for their preparation and use are described. As an example, a polyaniline-graphite nanoplatelet nanocomposite may be used to adsorb carbon dioxide..
|Method for determining platelet-associated analytes|
The present invention relates to a routine in vitro method for determining platelet-associated analytes, for example vwf, factor xiii, fibrinogen or d-dimer, in a sample of platelet-rich plasma.. .
|Method of using composite of silver nanoparticles and nanosilicate platelets to inhibit growth of silver-resistant bacteria|
The present invention provides a method of using a composite of spherical silver nanoparticles and layered inorganic clay, in particular nanosilicate platelets, for inhibiting the growth of silver-resistant bacteria. The layered inorganic clay serves as carriers of the silver nanoparticles and disperses them.
|Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit|
Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including ri, aix and sevr. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function.
|Composite flame barrier laminate for a thermal and acoustic insulation blanket|
A multilayer laminate comprising a first polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, a first adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c., an inorganic refractory layer comprising platelets in an amount of at least 85% by weight with a dry areal weight of 15 to 50 gsm and having a residual moisture content of no greater than 10 percent by weight, a second adhesive layer having an areal weight of from 4 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c. And a second polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 minutes..
|Composite laminate for a thermal and acoustic insulation blanket|
A multilayer laminate comprising in order, a polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, an adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c. And an inorganic refractory layer wherein the refractory layer comprises platelets in an amount at least 85% by weight with a dry areal weight of 15 to 50 gsm and has a residual moisture content of no greater than 10 percent by weight..
|Apparatus and method of platelet multi-function analysis, and micro stirring chip|
An apparatus and method for platelet multi-function analysis using measurement of electrical characteristics, and a stirring microchip are provided. The apparatus for platelet multi-function analysis includes a stirring microchip that has a sample storage chamber formed therein to hold a blood sample, and in which an inner part of the sample storage chamber is coated with reagents composed of collagen and epinephrine, or collagen and adp.
|Method for the enumeration of mammalian micronucleated erythrocyte populations, while distinguishing platelets and/or platelet-associated aggregates|
A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains dna (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
|Composite laminate for a thermal and acoustic insulation blanket|
A multilayer laminate for use as a flame barrier in an aircraft comprising (i) a polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, (ii) an adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c., (iii) an inorganic refractory layer, and (iv) aramid paper comprising from 50 to 90 weight percent of aramid fibers and from 10 to 50 weight percent of meta-aramid binder wherein the inorganic refractory layer of (iii) comprises platelets in an amount of at least 85% by weight with a dry areal weight of 15 to 50 gsm and a residual moisture content of no greater than 10 percent by weight.. .
|Delivery of compounds with rehydrated blood cells|
Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets..
|Separation membrane, method of producing the same and separation membrane module using the separation membrane|
A separation membrane includes a membrane comprising a polymer, characterized in that a functional layer is formed on the surface in one side of the membrane, the peak area percentage of carbon derived from ester group measured by the electron spectroscopy for chemical analysis (esca) on the surface of the preceding functional layer is 0.1% (by atomic number) or more but not more than 10 (% by atomic number), and the peak area percentage of carbon derived from ester group measured by the electron spectroscopy for chemical analysis (esca) on the surface opposite to the functional layer is not more than 10 (% by atomic number). A separation membrane module suffering from little sticking of organic matters, proteins, platelets and so on is provided with the separation membrane as a built-in membrane..
|Selectively coating luminal surfaces of stents|
With abluminal side of a stent masked, the luminal side of the stent is selectively coated with a substance, such as an anti-coagulant, a platelet inhibitor and/or a pro-healing substance. The stent can be masked by inserting it into a rigid mandrel chamber or by compressing a masking sleeve onto the outer side of the stent.
|Ultra high performance concrete reinforced with low-cost graphite nanomaterials and microfibers, and method for production thereof|
Ultra-high-performance cementitious materials are made using suitably functionalized and relatively low-cost carbon nanofibers and graphite platelets. Polyelectrolytes and surfactants are physisorbed upon these graphite nanomaterials in water, and dispersion of nanomaterials in water is achieved by stirring.
|Method for producing a porous particle composite for an electrical insulating paper|
A method is provided for producing an electrical insulation paper having a particle composite. The method involves mixing a dispersion of particles in platelet form, a carrier fluid and a functionalizing agent which is distributed in the carrier fluid and has a proportion by mass in the dispersion corresponding to a predetermined mass ratio based on the proportion by mass of the particles.
|Viral inactivated platelet extract, use and preparation thereof|
Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.. .
|Pdgf induced cell homing|
Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a tissue defect.
|Production of red blood cells and platelets from stem cells|
This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a stem cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) agonist. In some embodiments the stem cell is a pluripotent stem cell.
|Methods of controlling polymorphism in organic-free synthesis of na-zeolites and zeolite crystals formed therefrom|
Methods of controlling crystal polymorphism in organic-free synthesis of na-zeolites and the zeolite crystals formed using those methods are provided. The methods disclosed herein create certain types of zeolite crystals more efficiently than other previously known methods.
|Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury|
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
|Backing layers for floor coverings|
The present invention relates to a backing film for a resilient floor covering comprising (a) a first layer and (b) a second layer, wherein the first layer contains a first filler in an amount of from 10 to 80% by weight and the second layer contains a second filler in an amount of from 10 to 80% by weight and wherein the first filler is a platelet type filler.. .
|Anti-platelet membrane glycoprotein vi monoclonal antibody|
The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) it specifically binds to human platelet membrane glycoprotein vi (gpvi); b) the function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) it at least partially depletes gpvi on the platelet membrane by contacting with a platelet.. .
|Methods for separating constituents of biologic liquid mixtures|
Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (prp) can be obtained rapidly and is ready for immediate injection into the host.
|Platelet resuspension method and apparatus|
A method is disclosed for resuspending a concentrated blood component collected in a single-use processing chamber that is mounted to a rotatable support of a centrifugal collection system. A resuspension solution is introduced to the single-use processing chamber constraining the concentrated blood component.
|Filter for removing substances from blood or from blood derivatives, and a method for obtaining it|
A filter for removing substances, including leukocytes and platelets by way of non-limiting example, from whole blood or from blood derivatives, the filter includes a casing containing a layered filter element, at least one layer of this latter being coated with polyurethane; this polyurethane has a number average molecular weight between 10,000 and 20,000 dalton. A method for forming the layered filter element for a filter such as mentioned above, in which at least one layer of this filter element is impregnated with polyurethane by immersing it in a container of a mixture in which the polyurethane is present.
|Anti-wear performance of lubricants using carbon nanoplatelets|
Provided are a lubricating engine oil and a method of improving wear protection in an engine lubricated with such lubricating oil. The method includes using as the lubricating oil a formulated oil comprising a lubricating oil base stock as a major component, an antiwear additive as a first minor component, and carbon nanoplatelets as a second minor component.
|Platelet analysis system|
A method for diagnosis of hit (heparin-induced thrombocytopenia) in a patient's serum or plasma sample and a system comprising kits for performing the method.. .
|Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates|
Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume.
|Novel anti-platelet compound addition salt|
The present invention relates to a use of haloid acid salt and sulfonate of a compound of formula i and a salt of the compound of formula i in preparation of medicament for preventing or treating diseases caused by thrombosis or embolism. The present invention provides acid addition salts, especially haloid acid and sulfonic acid addition salts of a compound of formula i having high inhibition effect on platelet aggregation, and preparation method of the same, a medicament comprising the same, and a use and/or method for preventing or treating diseases caused by thrombosis or embolism..
|Inhibitors of protein kinases|
The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma..
|Therapeutic agents with improved fibrinogen binding|
Therapeutic agents with improved fibrinogen binding properties are described. The agents are suitable for use as artificial platelets, or for formation of biogels.
|Protein detection using three-dimensional carbon microarrays|
The potential of aptamers as ligand binding molecule have opened new avenues in the development of biosensors for proteins, such as cancer oncoproteins. Disclosed herein is a label-free detection strategy using signaling aptamer/protein binding complex for proteins, such as platelet-derived growth factor (pdgf-bb) oncoprotein.
|Derivation and maturation of synthetic and contractile vascular smooth muscle cells from human pluripotent stem cells|
Embryonic vascular smooth muscle cells (vsmcs) have a synthetic phenotype (syn-vsmc), but in adults, they commit to the mature contractile phenotype (con-vsmc). Con-vsmcs differ from syn-vsmc derivatives in condensed morphology, prominent filamentous cytoskeleton proteins, elastin production and assembly elastin, low proliferation, numerous active caveolae, enlarged endoplasmic reticulum, ample stress fibers and bundles, as well as high contractility.
|Enhanced autologous growth factor production and delivery system|
Systems and methods for producing enhanced blood serum with concentrated growth factors and/or prophylactically and therapeutically active proteins. An autologous blood product is obtained from a donor and then incubated into a containment device (sterile container) that includes a source of cells or tissue (for example, autologous, allogeneic, or xenographic tissue, or combinations thereof).
|Heteromultivalent nanoparticle compositions|
A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.. .
|Benzimidazole derivatives as pi3 kinase inhibitors|
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kβ, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
|Weather-resistant pearlescent pigments, process for the production and use thereof|
The present invention relates to a weather-resistant pearlescent pigment which consists of a platelet-shaped substrate coated with one or more highly refractive metal oxides, the platelet-shaped substrate being selected from the group consisting of synthetic mica flakes, glass flakes, sio2 flakes, al2o3 flakes, synthetic boehmite flakes, biocl flakes and mixtures thereof, and a top layer, wherein the top layer consists of the following layers: a) a cerium-containing layer, selected from the group consisting of cerium oxide, cerium hydroxide, hydrated cerium oxide, and mixtures thereof, the cerium-containing layer being applied directly to the highly refractive metal oxide layer, and b) an organic-chemical compatibilizing layer, which comprises the reaction products of oligomeric silanes, wherein the oligomeric silanes have one or more amino groups, the organic-chemical compatibilizing layer being applied directly to the cerium-containing layer a).. .
|Methods for the treatment or prophylaxis of thrombosis or embolism|
The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (s)oxo-clopidogrel or its derivative of the formula iia in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation.
|Reagent for blood cell counting and blood analysis method|
Disclosed is a novel reagent for blood cell counting and a novel blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body. The reagent for blood cell counting is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is an aqueous solution containing a chloroquine salt..
|Graphite nanoplatelets for thermal and electrical applications|
This disclosure concerns a procedure for bulk scale preparation of high aspect ratio, 2-dimensional nanoplatelets comprised of a few graphene layers, gn. N may, for example, vary between about 2 to 10.
|Bio-implantable devices having super-hydrophobic surface and method for manufacturing thereof|
The present disclosure relates to a bioimplantable device having a superhydrophobic surface and a method for manufacturing the same. The bioimplantable device, which includes a biocompatible substrate and a superhydrophobic nanostructure formed on the surface of the biocompatible substrate, is capable of preventing blood clot formation by blocking contact with proteins, water, blood platelets, etc.
|Composition of 5-nitrobenzoate derivatives as anti-metastatic agent that inhibits tumor cell-induced platelet aggregation|
And the preparation method therefor, wherein r is referred to hydrogen (h), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-nitrobenzoate derivatives of formula i do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (tcipa), and further specifically inhibits podoplanin-induced platelet aggregation.
|Cyclic peptides, their preparation and their use as inhibitors of the platelet adhesion|
The present invention relates to compounds of the formula (i), in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17, r18, x1, x2, x3 and x4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von willebrand factor (vwf) and the blood platelet receptor glycoprotein ib-ix-v complex (gpib), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases.
|Enhanced durability performance of lubricants using functionalized metal phosphate nanoplatelets|
A method for improving wear protection in an engine lubricated with a lubricating oil by using as the lubricating oil a formulated oil having a hths viscosity of less than 2.6 cp at 150° c. The formulated oil has a composition including a major amount of a lubricating oil base stock and a minor amount of metal phosphate nanoplatelets.
|Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo|
The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction..
|Highly lustrous silver-colored pigments with high opacity and metallic appearance, process for the preparation thereof and use of same|
A silver-colored pigment is provided having a nonmetallic platelet-shaped substrate and at least one ilmenite-containing coating, wherein the nonmetallic platelet-shaped substrate is a nonmetallic platelet-shaped synthetic substrate and the amount of iron compounds, calculated as elemental iron, in the pigment is less than 5.0% by weight, based on the total weight of the pigment. Processes for preparing the pigment also are provided..